Clinical pharmacology of anti-angiogenic drugs in oncology

Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two decades. Two types of anti-angiogenics have been approved: monoclonal antibodies and derivatives, which are injected and target the extracellular part of a receptor, and protein kinase inhibitors, which are orally taken small molecules targeting the intra-cellular Adenosine Triphosphate −pocket of different kinases.

Source: Critical Reviews in Oncology Hematology - September 1, 2017 Category: Cancer & Oncology Authors: P. Gougis, J. Wassermann, J.P. Spano, N. Keynan, C. Funck-Brentano, J.E. Salem Source Type: research